Back to Search Start Over

Mucopolysaccharidoses : quand y penser ?

Authors :
G. Touati
Thierry Levade
Francis Gaches
F. Catros
Nadia Belmatoug
Martin Michaud
S. Ancellin
Source :
La Revue de Médecine Interne. 41:180-188
Publication Year :
2020
Publisher :
Elsevier BV, 2020.

Abstract

Mucopolysaccharidosis are lysosomal storage diseases, secondary to the accumulation of mucopolysaccharides. Type 1 mucopolysaccharidosis is the most common form and affects between 0.69 and 1.66 newborns per 100,000. The severity of mucopolysaccharidosis is variable with lethal forms in utero and attenuated forms diagnosed in adults. The most common symptoms are short stature, facial dysmorphism, chronic articular pains that can mimic chronic inflammatory rheumatism, axial and peripheral bone involvement, hepatosplenomegaly and an early carpal tunnel. Depending on the type of mucopolysaccharidosis, corneal, cerebral or cardiac involvements are possible. Screening is based on the analysis of urinary glycosaminoglycans. The deficient enzyme assay and the gene analysis confirm the diagnosis. Mucopolysaccharidosis recognition is important for patient management and family screening. In addition, specific enzyme replacement therapy exists for certain types of mucopolysaccharidosis. Role of clinician is important to evoke and diagnose mucopolysaccharidosis.

Details

ISSN :
02488663
Volume :
41
Database :
OpenAIRE
Journal :
La Revue de Médecine Interne
Accession number :
edsair.doi...........af5b8c28c9a90c5a88fbbb83ac3a0c0d
Full Text :
https://doi.org/10.1016/j.revmed.2019.11.010